Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.35 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.33 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1298020 | 1.00 | RAB9A (0.42) | RAB9ATSHRHSP90AA1HSP90AB1GRM2 | |
| SCHEMBL1298024 | 1.00 | RAB9A (0.42) | RAB9ATSHRHSP90AA1HSP90AB1GRM2 | |
| SCHEMBL10329700 | 1.00 | RAB9A (0.42) | RAB9ATSHRHSP90AA1HSP90AB1GRM2 | |
| SCHEMBL1297747 | 1.00 | RAB9A (0.42) | RAB9ATSHRHSP90AA1HSP90AB1GRM2 | |
| SCHEMBL1297720 | 0.92 | TSHR (0.45) | RAB9ATSHRHSP90AA1HSP90AB1ALDH1A1 | |
| SCHEMBL1297664 | 0.86 | RAB9A (0.40) | RAB9ATSHRHSP90AA1HSP90AB1GRM2 | |
| SCHEMBL1297661 | 0.85 | RAB9A (0.42) | RAB9ATSHRHSP90AA1HSP90AB1GRM2 | |
| SCHEMBL27296220 | 0.85 | TSHR (0.43) | RAB9ATSHRHSP90AA1HSP90AB1ALDH1A1 | |
| SCHEMBL1296117 | 0.83 | RAB9A (0.46) | RAB9ATSHRSLC18A2 | |
| SCHEMBL1196705 | 0.82 | RAB9A (0.45) | RAB9ATSHRSLC18A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070007489-A1 | Heat transfer medium composition | SHISHIAI-KABUSHIKIGAISHA (JP) | 2007-01-11 | — | — | US | claimed |
| EP-1698678-A1 | HEAT CARRIER COMPOSITION | Shishiai-Kabushikigaisha (JP) | 2006-09-06 | — | — | EP | claimed |
| US-8222240-B2 | Use of substituted cyclopropane acid derivatives for producing drugs for use in the treatment of metabolic syndrome | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-07-17 | — | — | US | disclosed |
| EP-1827415-B1 | CYCLOPROPANE ACID DERIVATIVES FOR THE REDUCTION OF LIPID LEVELS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-01-20 | — | — | EP | disclosed |
| US-20090088474-A1 | USE OF SUBSTITUTED CYCLOPROPANE ACID DERIVATIVES FOR PRODUCING DRUGS FOR USE IN THE TREATMENT OF METABOLIC SYNDROME | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-04-02 | — | — | US | disclosed |
| US-20080045590-A1 | USE OF SUBSTITUTED CYCLOPROPANE ACID DERIVATIVES FOR PRODUCING DRUGS FOR USE IN THE TREATMENT OF METABOLIC SYNDROME | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| US-20070007489-A1 | Heat transfer medium composition | SHISHIAI-KABUSHIKIGAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1698678-A1 | HEAT CARRIER COMPOSITION | Shishiai-Kabushikigaisha (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045590-A1 | USE OF SUBSTITUTED CYCLOPROPANE ACID DERIVATIVES FOR PRODUCING DRUGS FOR USE IN THE TREATMENT OF METABOLIC SYNDROME | CYP27A1, CYP11B2, CYP11B1 | RAB9A 2758/4885TSHR 1717/4885HSP90AA1 1329/4885 |
| US-20090088474-A1 | USE OF SUBSTITUTED CYCLOPROPANE ACID DERIVATIVES FOR PRODUCING DRUGS FOR USE IN THE TREATMENT OF METABOLIC SYNDROME | FFAR1, FFAR2, FFAR3 | RAB9A 2351/4885TSHR 496/4885HSP90AA1 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.